03.04.13
As a result of a new licensing deal with Imprimis Pharmaceuticals, resolutionMD will have exclusive rights to the Accudel transdermal delivery technology, enabling the development of new anti-cellulite formulations.. ResolutionMD expects to launch its lead anti-cellulite product in the second quarter of 2013.
Under the terms of the agreement, resolutionMD will pay Imprimis a licensing royalty on the U.S. and international sales.
"We are extremely pleased to have reached an agreement with resolutionMD for our patented Accudel delivery technology and a related pending patent for our unique formulation. We believe this initial license and product launch may lead to future opportunities to use our technology in other cosmeceutical industry applications," stated Mark L. Baum, CEO, Imprimis Pharmaceuticals.
Brian Riley, president / CEO resolutionMD, added, "We believe that Imprimis's patented Accudel delivery technology in our proprietary anti-cellulite formulation has significant potential in the professional skin care market, not only in the U.S., but internationally as well. The Accudel Anti-Cellulite formula will be the flagship product for resolutionMD."
Under the terms of the agreement, resolutionMD will pay Imprimis a licensing royalty on the U.S. and international sales.
"We are extremely pleased to have reached an agreement with resolutionMD for our patented Accudel delivery technology and a related pending patent for our unique formulation. We believe this initial license and product launch may lead to future opportunities to use our technology in other cosmeceutical industry applications," stated Mark L. Baum, CEO, Imprimis Pharmaceuticals.
Brian Riley, president / CEO resolutionMD, added, "We believe that Imprimis's patented Accudel delivery technology in our proprietary anti-cellulite formulation has significant potential in the professional skin care market, not only in the U.S., but internationally as well. The Accudel Anti-Cellulite formula will be the flagship product for resolutionMD."
